Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu)
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Meningococcal A and C Polysaccharide Conjugate Vaccine is a bivalent, lyophilized conjugate vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., a subsidiary of Chongqing Zhifei Biological Products. It is designed to provide immune protection against meningococcal meningitis caused by *Neisseria meningitidis* serogroups A and C. The vaccine contains 10 μg each of purified capsular polysaccharides from serogroups A and C, each chemically conjugated to a tetanus toxoid carrier protein. This conjugation converts the polysaccharides into T-cell dependent antigens, which enhances immunogenicity and induces immunological memory, particularly in infants and young children. Formulated without an adjuvant, the vaccine is administered via intramuscular injection. It received clinical approval from China's State Food and Drug Administration (SFDA) in September 2015 and is indicated for individuals aged 3 months and older.
- Other names
- Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine (Tetanus Toxoid Conjugate)MenAC-TT (Zhifei Lvzhu)Meningococcal A and C Polysaccharide Conjugate Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal A and C Polysaccharide Conjugate Vaccine (Zhifei Lvzhu).